Jean Ruelle

Dr. Jean Ruelle


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJean Ruelle
Jean Ruelle
LDLaurent Debaisieux
Laurent Debaisieux
EVEllen Vancutsem
Ellen Vancutsem
ABAnnelies De Bel
Annelies De Bel
MDMarie-Luce Delforge
Marie-Luce Delforge
PGPatrick Goubau
Patrick Goubau
Current real-time PCR-based HIV-1 viral load (VL) assays allow the detection of residual viraemia in antiretroviral-treated patients. The clinical outcome of HIV1 patients experiencing low-level replication (<50 cop/mL) in comparison with fully suppressed patients is currently debated. We analysed variability of 3 VL assays <50 cop/mL, and evaluated the reproducibility of viral blips <100 cop/mL.

27 February 2008 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJean Ruelle
Jean Ruelle
FRFrançois Roman
François Roman
AVAnne-Thérèse Vandenbroucke
Anne-Thérèse Vandenbroucke
CLChristine Lambert
Christine Lambert
KFKatrien Fransen
Katrien Fransen
PGPatrick Goubau
Patrick Goubau
Background: Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply for HIV-2. Data about antiretroviral (ARV) drug efficacy and resistance mutations is scarce.Methods: Clinical data about HIV-2 infected patients in Belgium and Luxembourg were collected and the effect of ARV therapy on plasma viral load and CD4 counts were analysed. Viral RNA encoding for protease (PR) and reverse transcriptase (RT) from ARV-naïve and treated patients were sequenced.Results: Sixty-five HIV-2 infected patients were included in this cohort. Twenty patients were treated with 25 different ARV combinations in a total of 34 regimens and six months after the start of ARV therapy, only one third achieved viral load suppression. All of these successful regimens bar one contained protease inhibitors (PIs). Mean CD4 gains in the group of viral load suppressors and the group of patients treated with PI-containing regimens were respectively significantly higher than in the group of non-suppressors and the group of PI-sparing regimens. The most frequent mutations selected under therapy (compared to HIV-2 ROD) were V71I, L90M and I89V within PR. Within RT, they were M184V, Q151M, V111I and K65R. All of these mutations, except K65R and M184V, were also found in variable proportions in ARV-naïve patients.Conclusion: Despite a high rate of ARV treatment failure, better virological and immunological results were achieved with PI-containing regimens. The analysis of polymorphic positions and HIV-2 specific mutations selected during therapy showed for the first time that transmission of drug resistant viruses has occurred in Belgium and Luxembourg. The high heterogeneity in ARV combinations reflects a lack of guidelines for the treatment of HIV-2 infection.

3 November 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FCFor the BREACH (Belgian Research on AIDS and HIV Consortium)
For the BREACH (Belgian Research on AIDS and HIV Consortium)
DBDominique Van Beckhoven
Dominique Van Beckhoven
EFEric Florence
Eric Florence
JRJean Ruelle
Jean Ruelle
JDJ. Deblonde
J. Deblonde
ASA. Sasse
A. Sasse
The Belgian HIV epidemic is largely concentrated among men who have sex with men and Sub-Saharan Africans. We studied the continuum of HIV care of those diagnosed with HIV living in Belgium and its associated factors. Data on new HIV diagnoses 2007–2010 and HIV-infected patients in care in 2010–2011 were analysed. Proportions were estimated for each sequential stage of the continuum of HIV care and factors associated with attrition at each stage were studied. Of all HIV diagnosed patients living in Belgium in 2011, an estimated 98.2 % were linked to HIV care, 90.8 % were retained in care, 83.3 % received antiretroviral therapy and 69.5 % had an undetectable viral load (<50 copies/ml). After adjustment for sex, age at diagnosis, nationality and mode of transmission, we found lower entry into care in non-Belgians and after preoperative HIV diagnoses; lower retention in non-Belgians and injecting drug users; higher retention in men who have sex with men and among those on ART. Younger patients had lower antiretroviral therapy uptake and less viral suppression; those with longer time from diagnosis had higher ART uptake and more viral suppression; Sub-Saharan Africans on ART had slightly less viral suppression. The continuum of HIV care in Belgium presents low attrition rates over all stages. The undiagnosed HIV-infected population, although not precisely estimated, but probably close to 20 % based on available survey and surveillance results, could be the weakest stage of the continuum of HIV care. Its identification is a priority along with improving the HIV care continuum of migrants.

1 April 2009 in Journal of Clinical Virology
Verified
Journal Article
Closed access
JRJean Ruelle
Jean Ruelle
KJKarima Jnaoui
Karima Jnaoui
ILIsabelle Lefèvre
Isabelle Lefèvre
NLNajet Lamarti
Najet Lamarti
PGPatrick Goubau
Patrick Goubau

29 November 2010 in Retrovirology
Verified
Journal Article
Open access
PDF file
DBDanielle Perez Bercoff
Danielle Perez Bercoff
PTPerrine Triqueneaux
Perrine Triqueneaux
CLChristine Lambert
Christine Lambert
AOAboubacar Alassane Oumar
Aboubacar Alassane Oumar
ATAnne-Marie Ternes
Anne-Marie Ternes
JRJean Ruelle
Jean Ruelle
Human Immunodeficiency Virus type 2 is naturally resistant to some antiretroviral drugs, restricting therapeutic options for patients infected with HIV-2. Regimens including integrase inhibitors (INI) seem to be effective, but little data on HIV-2 integrase (IN) polymorphisms and resistance pathways are available.

1 October 2013 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
JRJean Ruelle
Jean Ruelle
MIMarie-Gabrielle Ingels
Marie-Gabrielle Ingels
KJKarima Jnaoui
Karima Jnaoui
NANathalie Ausselet
Nathalie Ausselet
AVAnne Vincent
Anne Vincent
PGPatrick Goubau
Patrick Goubau
Transmitted drug resistance (TDR) influencing nonnucleoside reverse transcriptase inhibitor (NNRTI) activity is increasing among new HIV-1 patients in several countries. As we recently observed an increase of K103N prevalence among new diagnoses in Belgium, we mined the Belgian national sequence database for homologous sequences. The earliest reverse transcriptase (RT) sequences available for drug-naive patients as well as sequences related to treatment failure were included. Fifty-five sequences were aligned and subjected to phylogenetic analysis, revealing the presence of a cluster of 29 virus sequences. All except one of those sequences were from antiretroviral (ARV)-naive patients at the time of sampling, and 22 had the K103N mutation. Epidemiological data of clustered patients were collected through the Institute of Public Health. Seventy-two percent of the clustered patients were infected through homosexual or bisexual contacts while the others reported heterosexual contacts only. All patients reside and were infected in Belgium. Sixteen were diagnosed between January 2011 and June 2012; 14 were aged between 18 and 29 years at the time of diagnosis. Nearly 60% of the clustered patients live close to the city of Namur, where HIV incidence substantially increased in the past 2 years. The identification of this transmission network advocates for local prevention reinforcement and underscores the need for continuous TDR monitoring. The spread of NNRTI TDR could affect ARV initiation schemes and prophylaxis strategies.